Overview

UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes

Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The aim is to investigate the safety and tolerability of intravenous infusion of allogeneic umbilical cord mesenchymal stem cells in pediatric patients diagnosed with newly onset type 1 diabetes
Phase:
NA
Details
Lead Sponsor:
Shanghai Changzheng Hospital